期刊文献+

康柏西普联合视网膜激光光凝治疗糖尿病性黄斑水肿45例的疗效 被引量:4

Therapeutic effects of conbercept combined with retinal laser photocoagulation on diabetic macular edema in 45 patients
原文传递
导出
摘要 目的探讨康柏西普联合视网膜激光光凝治疗糖尿病性黄斑水肿(DME)的疗效及对患者最佳矫正视力、黄斑中心凹厚度和房水血管内皮生长因子(VEGF)、人基质细胞衍生因子1(SDF-1)的影响。方法选取2016年11月至2019年12月丽水市人民医院收治的DME患者90例,根据随机数字表法分为对照组(视网膜激光光凝治疗)和研究组(对照组的基础上+康柏西普治疗),每组45例。比较两组患者疗效、最佳矫正视力、黄斑中心凹厚度和房水VEGF、SDF-1,记录两组治疗期间并发症发生情况。结果研究组临床总有效率为88.89%(40/45),高于对照组的68.89%(31/45),差异有统计学意义(χ^(2)=5.40,P<0.05)。治疗3个月后,研究组房水VEGF[(138.71±16.82)ng/L]、SDF-1[(415.18±24.87)mg/L]水平均低于对照组[VEGF(276.13±15.96)ng/L、SDF-1(526.06±22.91)mg/L](t=39.76、21.98,均P<0.001)。治疗3个月后,研究组黄斑中心凹厚度[(339.52±30.12)μm]、最佳矫正视力(0.47±0.08)分别与对照组[(398.65±28.23)μm、(0.36±0.09)]差异有统计学意义(t=6.13、9.61,均P<0.001)。两组并发症发生率差异无统计学意义[13.33%(6/45)比11.11%(5/45),χ^(2)=0.10,P>0.05]。结论康柏西普联合视网膜激光光凝治疗DME患者,疗效确切,可有效改善患者最佳矫正视力、黄斑中心凹厚度和房水VEGF、SDF-1水平,且不增加并发症发生率,具有一定的临床应用价值。 Objective To investigate the therapeutic effects of conbercept combined with retinal laser photocoagulation on diabetic macular edema(DME)and the effects of the combined therapy on best corrected visual acuity,macular fovea thickness,vascular endothelial growth factor(VEGF)and human stromal cell-derived factor 1(SDF-1)levels in aqueous humor of patients with DME.Methods Ninety patients with DME who received treatment in Lishui People's Hospital between November 2016 and December 2019 were included in this study.They were randomly assigned to undergo retinal laser photocoagulation(control group,n=45)or retinal laser photocoagulation combined with conbercept treatment(study group,n=45).Therapeutic effects,best corrected visual acuity,macular fovea thickness,and VEGF and SDF-1 levels in aqueous humor were compared between the two groups.The incidence of complications was compared between the two groups.Results Total response rate in the study group was significantly higher than that in the control group[88.89%(40/45)vs.68.89%(31/45),χ^(2)=5.40,P=0.020].After 3 months of treatment,VEGF and SDF-1 levels in aqueous humor were(138.71±16.82)ng/L and(415.18±24.87)mg/L,respectively,which were significantly lower than those in the control group[(276.13±15.96)ng/L,(526.06±22.91)mg/L,t=39.76,21.98,both P<0.001].After 3 months of treatment,macular fovea thickness and best corrected visual acuity in the study group were(339.52±30.12)μm and 0.47±0.08,respectively,which were significantly lower than those in the control group[(398.65±28.23)μm,0.36±0.09,t=6.13,9.61,both P<0.01].There was no significant difference in the incidence of complications between the two groups[13.33%(6/45)vs.11.11%(5/45),χ^(2)=0.10,P>0.05].Conclusion Conbercept combined with retinal laser photocoagulation for the treatment of DME has a definite therapeutic effect.The combined therapy can greatly improve the best corrected visual acuity,reduce macular fovea thickness,decrease VEGF and SDF-1 levels in aqueous humor,and does not increase the inci
作者 倪莉莎 李俊 刘林平 Ni Lisha;Li Jun;Liu Linping(Department of Ophthalmology,Lishui People's Hospital/The Sixth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,Zhejiang Province,China)
出处 《中国基层医药》 CAS 2022年第7期994-998,共5页 Chinese Journal of Primary Medicine and Pharmacy
基金 浙江省医药卫生科技计划项目(2016DY05065)。
关键词 黄斑水肿 糖尿病视网膜病变 激光凝固术 康柏西普 视力 眼睛 眼房水 血管内皮生长因子类 Macular edema Diabetic retinopathy Laser coagulation Conbercept ophthalmic injection Vision,ocular Aqueous humor Vascular endothelial growth factors
  • 相关文献

参考文献14

二级参考文献147

  • 1丰昀,朱小华,郭小健,田彧.玻璃体视网膜手术对糖尿病视网膜病变激光光凝术后玻璃体积血的疗效探讨[J].湖南师范大学学报(医学版),2008,5(2):23-26. 被引量:3
  • 2王伟伟,邹海东,朱剑锋,吴美芳.上海市北新泾街道社区糖尿病眼病3年防治调查[J].中国临床康复,2006,10(44):7-10. 被引量:16
  • 3王宁,许迅,邹海东,朱剑锋,王伟伟,潘凌.上海北新泾社区2型糖尿病患者黄斑水肿患病情况调查[J].中华眼科杂志,2007,43(7):626-630. 被引量:21
  • 4Diabetic Retinopathy Clinical Research Network,Googe J,Brucker AJ,et al.Randomized trial evaluating shortterm effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema following focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation[J].Retina,2011,31(6):1 009. 被引量:1
  • 5Diabetic Retinopathy Clinical Research Network.Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy[J].JAMA Ophthalmol,2013,131(3):283. 被引量:1
  • 6Bhavsar AR,Torres K,Glassman AR,et al.Evaluation of results1year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy[J].JAMA Ophthalmol,2014,132(7):889. 被引量:1
  • 7Bressler SB,Qin H,Melia M,et al.Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial[J].JAMA Ophthalmology,2013,131(8):1 033. 被引量:1
  • 8Mac Dougall NJ,Muir KW.Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion:systematic review and meta-analysis[J].J Cerebr Blood F Met,2011,31(3):807. 被引量:1
  • 9Acosta C,Alezzandrini A,Bafalluy J,et al.Defining Best Practice Standards for the Diagnosis and Management of Diabetic Retinopathy and Diabetic Macular Edema in Latin America[J].PAAO,2014,13(3 Suppl):3. 被引量:1
  • 10Klein KBE. Overview of epidemiologic studies of diabetic retinopathy [ J ]. Ophthalmic Epidemiol, 2007, 14 (4) : 179- 183. DOI: 10. 1080/ 09286580701396720. 被引量:1

共引文献249

同被引文献43

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部